Background

Our group has shown previously that microbiota can impact ulcerative colitis disease phenotypes by modulating invariant natural killer T (iNKT) cell functions. We further found that chemokine CXCL16 is responsible for this modulation, with germ-free (GF) mice having high CXCL16 level, large iNKT cell numbers and severe experimental ulcerative colitis outcome. In this study, we hypothesized that in addition to CXCL16 regulated functions, intestinal microbiota can directly impact iNKT cells by providing bacterial antigen, such as glycosphingolipids.

Methods

We generated a Bacteroides fragilis mutant (del SPT) that no longer produces any sphingolipids. We then mono-colonized GF mice using wild-type or del SPT mutant. Theses mice were further challenged with an experimental ulcerative colitis model—oxazolone colitis model and the disease phenotypes were evaluated.

Results

Results: We found that the wild-type B. fragilis mono-colonized mice have significantly lower colonic iNKT cell numbers than the mutant mono-colonized mice, which are similar to the GF mice. CXCL16 levels in both of the mono-colonized mice are as low as that of the conventional mice, indicating the existence of a new pathway for colonic iNKT cell regulation. When challenged in the oxazolone colitis model, the mutant-colonized mice were much more susceptible than the wild-type-colonized mice. These phenotypes were diminished when the mice were treated with CD1d antibody, indicating iNKT cell-specific functions were involved.

Conclusion(s)

Our study demonstrated that microbiota regulate colonic iNKT cells via a new and unknown pathway. This pathway uses components in bacterial sphingolipid biosynthesis and it points to a new direction for therapeutic intervention of ulcerative colitis.

This content is only available as a PDF.
You do not currently have access to this article.